# Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

> **NCT06361030** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 40 (estimated)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Cancer Non-resectable
- Pancreatic Ductal Adenocarcinoma, PDAC

## Interventions

- **DRUG:** surufatinib combined with gemcitabine plus nab-paclitaxel

## Key facts

- **NCT ID:** NCT06361030
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361030, "Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06361030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*